Merck & Co, shares trade near Wall Street consensus

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-27, 09:13.

Merck & Co. (US58933Y1055) trades on NASDAQ in New York, with analysts still clustering around a moderate buy call. TradingKey showed MRK at 128.40 dollars at the 06/26 close, while Pricetargets put the consensus target at 128.72 dollars.

Analysts stay close

The latest market snapshot on TradingKey lists a market cap of 317.74 billion dollars and a trailing P/E of 35.99. The same page shows the share price up 2.35 percent at the close on 06/26.

The consensus page at Pricetargets counts 20 analysts for MRK, with 12 Buy ratings, 7 Hold ratings and 0 Sell ratings. That mix leaves the stock in the Moderate Buy bracket.

Wall Street signal

For a US large-cap pharma name, that setup matters because the market is still paying close attention to earnings quality and pipeline visibility. A fresh analyst print from a named consensus source can keep the focus on MRK even on a quiet calendar day.

The company behind it

Merck & Co.'s core business spans prescription medicines and vaccines, with Keytruda and Gardasil among its best-known products. That portfolio gives the stock a clear link to oncology and immunization revenue.

The listing in brief

The Merck & Co. shares (US58933Y1055) trade on 2026-06-27, 09:13 on NASDAQ at 128.40 dollars.

Disclaimer: This article is for information only and does not constitute investment advice.